Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias.
Buccisano F, Rossi FM, Venditti A, Del Poeta G, Cox MC, Abbruzzese E, Rupolo M, Berretta M, Degan M, Russo S, Tamburini A, Maurillo L, Del Principe MI, Postorino M, Amadori S, Gattei V. Buccisano F, et al. Among authors: gattei v. Br J Haematol. 2004 Apr;125(2):203-12. doi: 10.1111/j.1365-2141.2004.04883.x. Br J Haematol. 2004. PMID: 15059143 Free article.
Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery.
Degan M, Bomben R, Bo MD, Zucchetto A, Nanni P, Rupolo M, Steffan A, Attadia V, Ballerini PF, Damiani D, Pucillo C, Poeta GD, Colombatti A, Gattei V. Degan M, et al. Among authors: gattei v. Br J Haematol. 2004 Jul;126(1):29-42. doi: 10.1111/j.1365-2141.2004.04985.x. Br J Haematol. 2004. PMID: 15198729 Free article.
Mutational status of IgVH genes consistent with antigen-driven selection but not percent of mutations has prognostic impact in B-cell chronic lymphocytic leukemia.
Degan M, Rupolo M, Bo MD, Stefanon A, Bomben R, Zucchetto A, Canton E, Berretta M, Nanni P, Steffan A, Ballerini PF, Damiani D, Pucillo C, Attadia V, Colombatti A, Gattei V. Degan M, et al. Among authors: gattei v. Clin Lymphoma. 2004 Sep;5(2):123-6. doi: 10.3816/clm.2004.n.019. Clin Lymphoma. 2004. PMID: 15453928
Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance.
Zucchetto A, Sonego P, Degan M, Bomben R, Dal Bo M, Russo S, Attadia V, Rupolo M, Buccisano F, Steffan A, Del Poeta G, Pucillo C, Colombatti A, Campanini R, Gattei V. Zucchetto A, et al. Among authors: gattei v. J Immunol Methods. 2005 Oct 20;305(1):20-32. doi: 10.1016/j.jim.2005.07.004. Epub 2005 Aug 8. J Immunol Methods. 2005. PMID: 16198366
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Del Poeta G, Del Principe MI, Consalvo MA, Maurillo L, Buccisano F, Venditti A, Mazzone C, Bruno A, Gianní L, Capelli G, Lo Coco F, Cantonetti M, Gattei V, Amadori S. Del Poeta G, et al. Among authors: gattei v. Cancer. 2005 Dec 15;104(12):2743-52. doi: 10.1002/cncr.21535. Cancer. 2005. PMID: 16284990 Free article. Clinical Trial.
296 results